Harriet Robinson

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint T cell vaccines for microbial infections
    Harriet L Robinson
    Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    Nat Med 11:S25-32. 2005
  2. ncbi request reprint Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine
    Harriet L Robinson
    Emory Vaccine Center of Emory University School of Medicine, Atlanta, GA 30322, USA
    Virology 352:285-94. 2006
  3. ncbi request reprint HIV/AIDS vaccines: 2007
    H L Robinson
    Yerkes National Primate Research Center, Emory Vaccine Center, Emory University School of Medicine, Emory University, Atlanta, Georgia, USA
    Clin Pharmacol Ther 82:686-93. 2007
  4. ncbi request reprint Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells
    Harriet L Robinson
    Emory University, Yerkes National Primate Research Center, Atlanta, Georgia 30329, Emory Vaccine Center, Atlanta, Georgia 30322, USA
    AIDS Res Hum Retroviruses 23:1555-62. 2007
  5. ncbi request reprint New hope for an AIDS vaccine
    Harriet L Robinson
    Vaccine Research Center, Emory University, Atlanta, Georgia 30329, USA
    Nat Rev Immunol 2:239-50. 2002
  6. ncbi request reprint Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations
    Michael Aidoo
    Centers for Disease Control and Prevention, 1600 Clifton Road, Mail Stop A 25, Atlanta, GA 30333, USA
    Vaccine 25:6474-81. 2007
  7. pmc Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques
    Shanmugalakshmi Sadagopal
    Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
    J Virol 82:4149-53. 2008
  8. pmc Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2
    Shanmugalakshmi Sadagopal
    Yerkes National Primate Research Center of Emory University, 954 Gatewood Dr, Atlanta, GA 30329, USA
    J Virol 79:3243-53. 2005
  9. ncbi request reprint HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges
    Dennis Ellenberger
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Mail Stop G 19, 1600 Clifton Road, Atlanta, GA 30333, USA
    Virology 352:216-25. 2006
  10. ncbi request reprint Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques
    James M Smith
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 20:654-65. 2004

Research Grants

  1. BASIC PRINCIPLES OF TRANSFECTION INITIATED IMMUNIZATION
    Harriet Robinson; Fiscal Year: 2001
  2. DNA/MWA Immunogens, Cross-clade Immune Responses
    Harriet Robinson; Fiscal Year: 2005

Collaborators

Detail Information

Publications47

  1. ncbi request reprint T cell vaccines for microbial infections
    Harriet L Robinson
    Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    Nat Med 11:S25-32. 2005
    ..To overcome this, researchers who are developing HIV/AIDS vaccines have turned to the elicitation of cellular immunity, or 'T cell vaccines,' which recognize and kill infected cells...
  2. ncbi request reprint Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine
    Harriet L Robinson
    Emory Vaccine Center of Emory University School of Medicine, Atlanta, GA 30322, USA
    Virology 352:285-94. 2006
    ..The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-adjuvanted group...
  3. ncbi request reprint HIV/AIDS vaccines: 2007
    H L Robinson
    Yerkes National Primate Research Center, Emory Vaccine Center, Emory University School of Medicine, Emory University, Atlanta, Georgia, USA
    Clin Pharmacol Ther 82:686-93. 2007
    ..These new vaccines elicit T cells capable of recognizing and killing virus-infected cells. Brief synopses are given for six vaccines currently advancing in human trials...
  4. ncbi request reprint Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells
    Harriet L Robinson
    Emory University, Yerkes National Primate Research Center, Atlanta, Georgia 30329, Emory Vaccine Center, Atlanta, Georgia 30322, USA
    AIDS Res Hum Retroviruses 23:1555-62. 2007
    ..The highest responses were elicited to Gag, followed by Env and then Pol. In two of six macaques, the vaccine also elicited low levels of neutralizing Ab for easy to neutralize clade B isolates...
  5. ncbi request reprint New hope for an AIDS vaccine
    Harriet L Robinson
    Vaccine Research Center, Emory University, Atlanta, Georgia 30329, USA
    Nat Rev Immunol 2:239-50. 2002
    ..The ultimate promise of these vaccines will be realized only when efficacy trials in humans are conducted...
  6. ncbi request reprint Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations
    Michael Aidoo
    Centers for Disease Control and Prevention, 1600 Clifton Road, Mail Stop A 25, Atlanta, GA 30333, USA
    Vaccine 25:6474-81. 2007
    ..These findings demonstrate that some vaccinated macaques appeared to be free from the challenge virus. Therefore, such T cell-based vaccines may provide some protection when challenge virus doses approach physiological equivalencies...
  7. pmc Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques
    Shanmugalakshmi Sadagopal
    Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
    J Virol 82:4149-53. 2008
    ..At euthanasia, all CD8, but no CD4, Gag epitopes detected during long-term control contained mutations...
  8. pmc Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2
    Shanmugalakshmi Sadagopal
    Yerkes National Primate Research Center of Emory University, 954 Gatewood Dr, Atlanta, GA 30329, USA
    J Virol 79:3243-53. 2005
    ..Overall, high titers of binding and neutralizing antibody persisted throughout the postchallenge period. Encouragingly, long-term control was effective in macaques of diverse histocompatibility types...
  9. ncbi request reprint HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges
    Dennis Ellenberger
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Mail Stop G 19, 1600 Clifton Road, Atlanta, GA 30333, USA
    Virology 352:216-25. 2006
    ..Therefore, improved non-human primate models for vaccine efficacy can provide novel insight and perhaps renew expectations for positive outcomes of human HIV clinical trials...
  10. ncbi request reprint Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques
    James M Smith
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 20:654-65. 2004
    ....
  11. pmc Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines
    Rama Rao Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    J Virol 76:7625-31. 2002
    ..Thus, MVA vaccines, as well as DNA/MVA vaccines, merit further evaluation for their ability to control the current AIDS pandemic...
  12. ncbi request reprint Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs
    Dennis Ellenberger
    Laboratory Branch, Centers for Disease Control and Prevention, Mail Stop G 19, Atlanta, GA 30333, USA
    Virology 340:21-32. 2005
    ..They also suggest that expression of different forms of VLP has a significant effect on elicited cellular and humoral immunity...
  13. pmc Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine
    Rama Rao Amara
    Vaccine Research Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Virol 76:6138-46. 2002
    ..Our results highlight the importance of immune responses to Env, as well as to Gag-Pol, in the control of immunodeficiency virus challenges and the protection of CD4(+) cells...
  14. pmc GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine
    Lilin Lai
    Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA Emory Vaccine Center, 954 Gatewood Road, Atlanta, GA 30322, USA
    Virology 369:153-67. 2007
    ..Animals with the highest avidity anti-Env Ab had 1000-fold reductions in peak viremia over those with the lowest avidity anti-Env Ab. The enhanced IgA response was associated with the best protection, but did not achieve significance...
  15. pmc Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines
    Sunil Kannanganat
    Vaccine Research Center, Department of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329, USA
    J Virol 81:12071-6. 2007
    ..001) with viral load. These results demonstrate a strong association between the maintenance of highly functional CD4 T cells producing three cytokines and control of HIV-1...
  16. pmc Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia
    Jun Zhao
    Emory Vaccine Center, Atlanta, Georgia 30329, USA
    J Virol 83:4102-11. 2009
    ..6) had limited breadth for incident isolates. Our results suggest that certain Envs can elicit nonneutralizing but high-avidity Ab with broad potential for blunting incident infections of the same clade...
  17. ncbi request reprint Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms
    Dennis Ellenberger
    HIV and Retrovirology Branch, Division of AIDS, STD, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U S Department of Health and Human Services, Atlanta, GA 30333, USA
    Virology 319:118-30. 2004
    ..The production of multiple antigenic forms, including fusion-competent VLPs, by candidate DNA vaccine constructs may provide immunologic advantages for induction of protective cellular and humoral responses against HIV-1 proteins...
  18. ncbi request reprint Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort
    Bill G Kapogiannis
    Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 22:272-82. 2006
    ..Longitudinal studies are clearly necessary to assess the impact of HAART on these parameters...
  19. ncbi request reprint Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine
    Jinyan Liu
    Emory Vaccine Center, Emory University School of Medicine and Yerkes National Primate Research Center, 954 Gatewood Road, Box 129, Atlanta, GA, USA
    Vaccine 24:3332-9. 2006
    ..The shallow dose-response curves for immunogenicity were observed post priming as well as post boosting of an MVA or a DNA prime...
  20. ncbi request reprint Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses
    James M Smith
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 21:140-4. 2005
    ..Thus, the ability of an HIV vaccine for one clade to protect against other clades may be more limited by the ability to provide CD4 T cell help than the ability to elicit CD8 effector functions...
  21. ncbi request reprint Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    Rama Rao Amara
    Vaccine Research Center, Yerkes Regional Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329, USA
    Vaccine 20:1949-55. 2002
    ..These highly promising findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic...
  22. pmc A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease
    Rama Rao Amara
    Divisions of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, 954 N Gatewood Rd, Atlanta, GA 30329, USA
    J Virol 79:15356-67. 2005
    ..These results demonstrate that addition of a DNA prime to a live attenuated virus provided better protection from disease following challenge than live attenuated virus alone...
  23. ncbi request reprint A new generation of HIV vaccines
    Rama Rao Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, 954, Gatewood Drive, NE, Atlanta, GA 30329, USA
    Trends Mol Med 8:489-95. 2002
    ..These recent vaccine successes in macaques raise hope that a vaccine can be developed that will successfully limit both the development of AIDS and viral transmission...
  24. pmc Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus
    Marcin Kwissa
    Vaccine Research Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA
    J Exp Med 204:2733-46. 2007
    ..Viral loads were inversely correlated with the magnitude and quality of the immune response. Thus, the immunogenicity of DNA vaccines can be augmented with TLR9-L plus FL...
  25. ncbi request reprint DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime
    James M Smith
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 20:1335-47. 2004
    ..Based on the breadth of the T cell response and a trend toward higher titers of anti-Env Ab, we are moving forward with human trials of the noncodon-optimized VLP-expressing DNA...
  26. ncbi request reprint Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques
    Rama Rao Amara
    Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA
    Virology 343:246-55. 2005
    ..6P control. They also suggest a dynamic relationship between neutralizing Ab, antigen load and anti-viral CD4 cells in the maturation of high-quality anti-viral CD8 T cells...
  27. ncbi request reprint Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge
    Suzan L Buge
    Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    AIDS Res Hum Retroviruses 19:891-900. 2003
    ..This trend did not reach significance in our animal groups of 8. We conclude that gp120 inoculations that fail to raise neutralizing antibody do not improve the efficacy of Gag-Pol-Env DNA/MVA vaccines...
  28. pmc Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges
    Yuyang Tang
    Vaccine Research Center, Yerkes National Primate Research Center, 954 Gatewood Road NE, Atlanta, GA 30329, USA
    J Virol 76:10147-54. 2002
    ..Thus, to date, control of the challenge infection has appeared to improve with time, with the decay rates for viral DNA being at the lower end of values reported for patients on highly active antiretroviral therapy...
  29. ncbi request reprint Emerging prospects for the disease-modifying treatment of Alzheimer's disease
    Lary C Walker
    Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30322, USA
    Biochem Pharmacol 69:1001-8. 2005
    ..These adverse events were not anticipated from preclinical studies with rodents; hence, more biologically relevant models, such as nonhuman primates, are needed to test the safety and efficacy of novel therapies for Alzheimer's disease...
  30. ncbi request reprint Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques
    Rama Rao Amara
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA
    Virology 334:124-33. 2005
    ..Our results demonstrate that the clade B DNA/MVA HIV vaccine elicits T cell responses against epitopes that are conserved in multiple clades and recognized by humans and macaques...
  31. pmc Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors
    Shin Sasaki
    Division of Microbiology and Immunology, Yerkes National Primate Research Center and Vaccine Research Center, Emory University School of Medicine, 954 Gatewood Road, Atlanta, GA 30329, USA
    J Virol 76:6652-9. 2002
    ..These biases were enhanced by the codelivered IRFs. Overall, under the conditions of our experiments, IRF-3 had good activity for T cells, IRF-7 had good activity for both antibody and T cells, and IRF-1 had good activity for antibody...
  32. pmc DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge
    Pragati Nigam
    Emory Vaccine Center, Department of Microbiology and Immunology, and Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, NE, Atlanta, GA 30329, USA
    Virology 366:73-83. 2007
    ..Thus, our results demonstrate the elicitation of long lasting protective immunity for a lethal monkeypox challenge by a DNA/MVA HIV-1 vaccine...
  33. pmc Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells
    Sunil Kannanganat
    Emory Vaccine Center, Department of Microbiology and Immunology, Yerkes National Primate Research Center, 954 Gatewood Road NE, Atlanta, GA 30329, USA
    J Virol 81:8468-76. 2007
    ....
  34. ncbi request reprint DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells
    Alp E Oran
    Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA
    J Immunol 171:1999-2005. 2003
    ..Studies in B cell knockout and hen egg lysozyme Ig transgenic mice revealed that B cells were required for the generation of IL-4-producing CD8(+) T cells...
  35. pmc Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines
    Vinod Bhaskara Pillai
    Yerkes National Primate Research Center and Emory Vaccine Center of Emory University School of Medicine, 954 Gatewood Road, Atlanta, GA 30329, USA
    Vaccine 26:1136-41. 2008
    ..Thus, under our experimental conditions, measurements for supercoiled vaccine DNA provided a more accurate assessment of the potential to prime a CD8 response than tests for expression in transiently transfected cells...
  36. pmc DNA vaccines: influenza virus challenge of a Th2/Tc2 immune response results in a Th2/Tc1 response in the lung
    Alp E Oran
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    J Virol 78:4376-80. 2004
    ..Thus, the type of memory T-cell response induced by DNA vaccination does not determine the type of response that will predominate at the site of an infection...
  37. ncbi request reprint Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development
    Dennis L Ellenberger
    HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Virology 302:155-63. 2002
    ..These data suggest that the consensus sequence generated from incident and prevalent infections may provide an appropriate sequence for a DNA vaccine and is largely representative of the major circulating viral strain...
  38. ncbi request reprint Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine
    Rick A Bright
    Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Virology 308:270-8. 2003
    ....
  39. ncbi request reprint Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines
    Harriet L Robinson
    J Infect Dis 194:1625-7. 2006
  40. ncbi request reprint Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 20:645-53. 2004
    ..In the accompanying paper, we show that MVA/HIV 48 provided efficient boosting of an HIV DNA vaccine...
  41. pmc Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3210, USA
    Vaccine 26:486-93. 2008
    ..These data suggest that for high immunogenicity, rMVAs should be engineered to produce the most recombinant protein that can be achieved without compromising the growth and stability of the rMVA...
  42. ncbi request reprint Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques
    Jin Su
    Department of Medicine, University of Toronto, Toronto, Canada
    Int Immunol 17:637-48. 2005
    ..It may thus help increase the supply of rhesus macaques in which epitope-specific immunity can be studied in the context of SIV vaccine design...
  43. pmc Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen
    Henry E Neuman de Vegvar
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    J Virol 77:11125-38. 2003
    ..These data suggest that the functional diversity of anti-SHIV B-cell responses is highly limited in the presence of persisting antigen...
  44. ncbi request reprint T cells versus HIV-1: fighting exhaustion as well as escape
    Harriet L Robinson
    Nat Immunol 4:12-3. 2003
  45. pmc Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 33, Room 1E19, 33 North Drive, MSC 3210, Bethesda, MD 20892, USA
    Virology 366:84-97. 2007
    ..These non-human primate studies support the clinical testing of recombinant MVA as an HIV vaccine and further demonstrate that MVA can provide long-term poxvirus immunity, essential for use as an alternative smallpox vaccine...
  46. ncbi request reprint Prime boost vaccines power up in people
    Harriet L Robinson
    Nat Med 9:642-3. 2003
  47. ncbi request reprint Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost
    Jinyan Liu
    Yerkes National Primate Research Center and Emory Vaccine Center of Emory University, Atlanta, GA, United States
    Vaccine 25:2951-8. 2007
    ..These results are in contrast to dose-response studies for MVA vectors expressing Gag, where only 2-3-fold increases in anti-Gag CD8 T cells were elicited by 100-fold increases in dose...

Research Grants2

  1. BASIC PRINCIPLES OF TRANSFECTION INITIATED IMMUNIZATION
    Harriet Robinson; Fiscal Year: 2001
    ..Post challenge studies will examine the effects of Th1- and Th2-biased responses on the control of infection and post challenge immunopathology. ..
  2. DNA/MWA Immunogens, Cross-clade Immune Responses
    Harriet Robinson; Fiscal Year: 2005
    ..abstract_text> ..